Skip to main content

Advertisement

Table 1 Association analysis between FBI-1 expression and the clinicopathological features of ovarian cancers

From: Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers

   Case assessed Score (mean ± SE) p-value
Diagnostic categories Benign 10 0 0.000a
  Borderline 19 7.83 ± 0.92 0.000a, 0.000b
  Primary cancer 111 12.31 ± 0.37 0.000a
  Metastatic foci 63 13.47 ± 0.46 0.036c
  Malignant ascites 17 14.11 ± 0.87 0.021c
Histological types of ovarian cancer Serous 43 12.53 ± 1.04 0.070d
  Endometrioid 36 11.82 ± 0.66  
  Clear cell 23 12.76 ± 0.53  
  Mucinous 9 12.11 ± 1.17  
Stage Stage I 42 11.30 ± 0.67 0.012e
  Stage II-IV 69 13.38 ± 0.42  
Grade Low (grade I) 32 12.22 ± 0.73 0.151f
  High (grade II and III) 79 12.39 ± 0.44  
Response to primary chemotherapy Sensitive 78 12.14 ± 0.45 0.246g
  Resistant 18 13.22 ± 0.92  
Survival months 0.53~188.57 (average: 44.7)
  1. a p Value reflects the comparison of each category vs. benign tumor.
  2. b p Value reflects the comparison of primary cancer vs. borderline.
  3. c p Value reflects the comparison of metastatic foci or malignant ascites versus primary cancer.
  4. d p Value reflects the comparison of clear cell carcinoma versus all the other histological types combined.
  5. e p Value reflects the comparison of stage I versus stage II-IV.
  6. f p Value reflects the comparison of low grade versus. high grade.
  7. g p Value reflects the comparison of chemosensitive versus chemoresistant.